TG Therapeutics TGTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.78M+291% | $23.04M-1.3% | $390.9M+9,975% | $28.19M+310% | $5.06M+147% | ||
| $32K+300% | $21K+133% | $17K+54.5% | $13K-31.6% | $8K-72.4% | ||
| $19.95M+33.2% | $15.65M+31.0% | $17.69M+50.2% | $16.36M+72.6% | $14.97M+60.3% | ||
| $3.86M— | —— | —— | —— | $0— | ||
| $285K-6.3% | $304K+0.3% | $304K-26.6% | $304K-52.4% | $304K-52.4% | ||
| $86.42M+41.8% | $40.24M+199% | $33.87M+5.4% | $41.4M+122% | $60.94M+339% | ||
| $13.28M-71.3% | —— | —— | —— | $46.31M+25.4% | ||
| $34.02M-47.8% | $2.01M— | —— | $5.97M-33.3% | $65.18M+62.0% | ||
| -$1.62M+12.8% | —— | -$277K— | -$515K-184% | -$1.86M-161% | ||
| -$5.99M-4,377% | —— | $9.17M-49.5% | $1.79M+259% | $140K-76.7% | ||
| -$6.72M-1,747% | —— | —— | —— | $408K— | ||
| $1.53M+1,575% | -$433K+13.6% | $420K+660% | -$181K+51.5% | -$104K-153% | ||
| $573K+26.5% | $432K-13.3% | $431K-13.3% | $432K-13.3% | $453K+11.3% | ||
| -$9.15M— | $0+100% | —— | —— | -$0+100% | ||
| -$424K+21.9% | -$519K+13.2% | -$519K+13.1% | -$518K+13.2% | -$543K+8.9% | ||
| -$10.66M-330% | $1.91M— | $30.63M+19.7% | $5.26M+601% | $4.63M+411% | ||
| -$17.89M+37.7% | —— | -$23.15M-89.7% | —— | -$28.72M-250% | ||
| $51K+104% | $67K+219% | $80K+233% | $42K— | $25K— | ||
| $11.25M-86.0% | $30M-59.3% | $77.75M-15.8% | $49.35M-31.0% | $80.4M+9.5% | ||
| -$0-100% | —— | —— | —— | $1.25M— | ||
| $21.06M-77.1% | $45.57M-21.3% | $31.31M-69.1% | $53.3M-23.6% | $92.06M+12.9% | ||
| -$9.86M+23.7% | —— | $46.36M+597% | -$3.99M— | -$12.93M-39.8% | ||
| $99.99M+1,533% | $0-100% | $78.24M+3,541% | $6.88M— | $6.12M— | ||
| $747.66M— | $0— | —— | —— | $0— | ||
| $763K+3,533% | -$453K— | $0— | $432K+4,420% | $21K+110% | ||
| $2.6M— | $0-100% | —— | —— | -$0— | ||
| $390.83M+6,505% | $0— | -$78.24M-158% | -$6.44M-4,873% | -$6.1M-61,120% | ||
| $363.07M+860% | $0— | -$55.03M-149% | -$3M— | -$47.75M-174% | ||
| $2.39M-61.2% | $5.91M-8.0% | $6.1M-14.2% | $6.1M+145% | $6.14M+151% | ||
| $3.44M— | $845K+69.0% | $1.96M— | $5.08M— | $0— | ||
| $285K-6.3% | $304K+0.3% | $304K-26.6% | $304K-52.4% | $304K-52.4% | ||
| -$5.99M-4,377% | —— | $9.17M-49.5% | $1.79M+259% | $140K-76.7% | ||
| -$424K+21.9% | -$519K+13.2% | -$519K+13.1% | -$518K+13.2% | -$543K+8.9% | ||
| -$10.66M-330% | $1.91M— | $30.63M+19.7% | $5.26M+601% | $4.63M+411% | ||
| -$1.62M+12.8% | —— | -$277K— | -$515K-184% | -$1.86M-161% | ||
| —— | $1.54M— | $1.54M— | $1.54M— | $1.54M— | ||
| $367K-72.5% | $383K-77.4% | $786K-56.7% | $1.28M-28.7% | $1.34M-20.0% | ||
| $573K+26.5% | $432K-13.3% | $431K-13.3% | $432K-13.3% | $453K+11.3% | ||
| -$0-100% | —— | —— | —— | $1.25M— | ||
| $21.06M-77.1% | $45.57M-21.3% | $31.31M-69.1% | $53.3M-23.6% | $92.06M+12.9% | ||
| $99.99M+1,533% | $0-100% | $78.24M+3,541% | $6.88M— | $6.12M— | ||
| $747.66M— | $0— | —— | —— | $0— | ||
| $48K0.0% | $46K-13.2% | $45K-15.1% | $46K-13.2% | $48K-9.4% | ||
| -$88K+58.7% | —— | -$14K+89.0% | —— | -$213K-709% | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$255M— | $0+100% | —— | —— | $0+100% | ||
| $1.13M— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $3.44M— | $845K+69.0% | $1.96M— | $5.08M— | $0— | ||
| -$17.95M+37.6% | —— | -$23.23M-90.0% | —— | -$28.74M-250% | ||
| -$17.95M+37.6% | —— | -$23.23M-90.0% | —— | -$28.74M-250% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does TG Therapeutics generate?
- TG Therapeutics (TGTX) generated -$95.4M in operating cash flow over the trailing twelve months.
- What is TG Therapeutics's free cash flow?
- After $240.0K of capital expenditures, TG Therapeutics's free cash flow was -$95.6M over the trailing twelve months, down 66.2% year over year.
- Where does TG Therapeutics's cash flow data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
